Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl-Reference-Cited by-同舟云学术

Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl

Published:2022-04-18 Issue:6 Volume:89 Page:737-750
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Sun Hao^ORCID,Cardinal Kristen A.,Wienkers Larry,Chin Alice,Kumar Vineet,Neace Calvin,Henderson Clark,Endres Christopher J.,Topletz-Erickson Ariel,Regal Kelly,Vo Alex,Alley Stephen C.,Lee Anthony J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04429-z.pdf

Reference26 articles.

1. Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609

2. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, Forero-Torres A, Peterson S (2020) Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther 19(4):976–987. https://doi.org/10.1158/1535-7163.MCT-19-0873

3. Borges VF, Ferrario C, Aucoin N, Falkson C, Khan Q, Krop I, Welch S, Conlin A, Chaves J, Bedard PL, Chamberlain M, Gray T, Vo A, Hamilton E (2018) Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol 4(9):1214–1220. https://doi.org/10.1001/jamaoncol.2018.1812

4. Shahrokh K, Cheatham TE 3rd, Yost GS (2012) Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen. Biochim Biophys Acta 1820(10):1605–1617. https://doi.org/10.1016/j.bbagen.2012.05.011

5. Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825–833. https://doi.org/10.1038/nrd1851

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of Structural Alerts for Reactive Metabolites in the Application SpotRM;Chemical Research in Toxicology;2024-08-01

2. Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities;Drug Metabolism and Disposition;2024-01-29

3. Xanthine Oxidoreductase and Aldehyde Oxidases;Reference Module in Biomedical Sciences;2024

4. Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for Tucatinib;Clinical Pharmacology & Therapeutics;2023-12-08

5. 50th Anniversary Celebration Collection Special Section on Mechanism-Based Predictive Methods in Drug Discovery and Development-Minireview Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter Inhibition^S;DRUG METAB DISPOS;2023